RegisterLogin

SD-1008

CAT: 0804-HY-107595-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-107595-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
SD-1008 is a potent JAK inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway[1].
CAS Number
[960201-81-4]
UNSPSC
12352005
Target
Apoptosis; JAK; STAT
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sd-1008.html
Purity
99.10
Solubility
10 mM in DMSO
Smiles
O=C([C@H]1[C@H](C2=O)N([C@H](C=C2)[C@H]1C(OC)=O)CC3=CC=CC=C3)OC
Molecular Formula
C18H19NO5
Molecular Weight
329.35
References & Citations
[1]Duan Z, et al. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol. 2007;72 (5) :1137-1145.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK2; STAT3

Related Products

CatalogName
HY-129602-01SD-36
HY-167092SD-1077
HY-172946SD-2301
HY-W015445-01SD-169
HY-121522-01SD-70
HY-164525SD-7300
HY-13227-01SD-208
HY-108019SD 8381
HY-169360-01SD-436
HY-150251-01SD-91

Alternative Products

CatalogName
MBS3841052-01SD 1008
574875SD-1008
A15364-10SD 1008 10mg
A15364-5SD 1008 5mg
A15364-50SD 1008 50mg
MBS3602249-01PRN 1008
sc-203426ABD 1008
BA2112-25CWHM-1008
TP2953-01CBP-1008
T35125We 1008

Popular Products